4.3 Review

Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?

期刊

CURRENT CARDIOLOGY REPORTS
卷 20, 期 11, 页码 -

出版社

SPRINGER
DOI: 10.1007/s11886-018-1047-y

关键词

Digoxin; Atrial fibrillation

资金

  1. Bayer Pharmaceuticals
  2. Janssen
  3. AstraZeneca
  4. HeartFlow
  5. NHLBI

向作者/读者索取更多资源

Purpose of Review A number of recent observational analyses have assessed clinical outcomes associated with digoxin use in patients with atrial fibrillation. In this review, we review these data and provide suggestions on the contemporary use of digoxin in patients with atrial fibrillation as supported by the recent evidence. Recent Findings Observational data from clinical trials and registries have provided variable results on the safety and efficacy of chronic digoxin use in patients with atrial fibrillation. In general, results have been consistent with an associated increase in adverse clinical outcomes with digoxin use in atrial fibrillation patients without heart failure. In atrial fibrillation patients with heart failure, while the weight of evidence suggested an associated risk with digoxin therapy, the results are inconsistent. Summary In patients with atrial fibrillation without heart failure, digoxin should generally be avoided. In atrial fibrillation patients with heart failure, digoxin should generally be reserved for patients that do not achieve adequate rate control or are not tolerant of other rate control therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据